Introduction
Acquired aplastic anemia (AA) is a disease that is characterized by bone marrow aplasia and peripheral blood pancytopenia. The incidence of acquired AA is approximately 2 per million in Europe and North America and 4-6 per million in East Asia. 1 In the presence of anemia and thrombocytopenia, a level of circulating neutrophils of o0.2, 0.2-0.5 or 40.5 Â 10 9 /l defines very severe, severe, or non-severe AA. Over the past two decades in vitro studies using AA bone marrow cells, have shown (i) a reduced number of hemopoietic progenitors (colony-forming units), 2 (ii) increased number of suppressor T cells releasing g interferon (IFN) 3 and recently, (iii) abnormalities of mesenchymal stem cells with reduced ability to inhibit T-cell function. 4 These results have led to the hypothesis that acquired AA is an immune-mediated disease of the bone marrow. 5, 6 The degree of progenitor cell depletion is of the order of 99%, as shown with long-term culture-initiating cells and is seen for decades after successful treatment with immunosuppressive therapy (IST). 7 Treatment of acquired SAA includes BMT and IST. The choice of therapy is based on (a) severity of the disease, (b) patients' age and (c) availability of a human leukocyte antigen (HLA) identical sibling. The estimated difference in the proportion of patients surviving event free after 5 years, after an HLA identical sibling BMT or IST as first-line therapy is based on severity of the disease and patient age. 8 Young patients with low neutrophil counts have a significant advantage if given a BMT first line. Older patients with higher neutrophil counts do better if given IST first line.
BMT from HLA identical siblings
Young patients with an HLA identical sibling are eligible for a BMT up-front, particularly when the neutrophil count is low. Standard conditioning regimen is cyclophosphamide (CY) 50 mg/kg/day Â 4 (CY 200 mg/kg), which will produce survival in excess of 80% in young patients (o30 years old) when the transfusion burden is low. 8 CY200 is free of long-term effects and fertility is conserved. Problems, however, remain: CY200 is close to the cardiotoxic dose and needs to be carefully calculated. Another problem is the lack of full engraftment, also known as mixed chimerism:
9 amplification of short tandem repeats can classify BMT recipients as (a) complete chimeras (40% of patients), (b) transient mixed chimeras (18% of patients), (c) stable mixed chimeras (20% of patients) and (d) progressive mixed chimeras. 10 The latter have a poor prognosis and should be monitored carefully when reducing cyclosporin A (CsA) post-BMT. In patients heavily transfused rejection has been reduced by introducing antilymphocyte globulin (ALG), 11 low-dose busulfan 12 or low-dose total body irradiation (TBI) or total lymphoid irradiation (TLI). Radiation and also busulfan, need to be used with caution owing to their potential oncogenic effect, 13 and fertility may also be compromised. GVHD is the other complication seen mainly in patients with complete chimerism: CsA or CsA with methotrexate (MTX) are currently standard GVHD prophylaxis.
BMT from unrelated donors
There have been two important studies in the setting of unrelated donor transplants for SAA: one from the USA 15 and one from Japan. 16 In the first, Deeg and coworkers reported the outcome of a program using de-escalating doses of radiation, from 6 to 2 Gy. Of the 20 patients who received 6 or 4 Gy, all engrafted and 10 (50%) survived, of the 13 who received 2 Gy, one (8%) failed to engraft and eight (62%) are alive. The Japanese report summarized the outcome of 154 patients undergoing an unrelated donor transplant: 11% rejected, 20% experienced acute GVHD, 30% chronic GVHD and 64% survive. Unfavorable factors for survival were older age (420 years), conditioning without antithymocyte globulin and a long (43 years) interval diagnosis transplant. The Japanese study included a large number of patients who received radiation either as total body or total node radiation.
Although radiation increases the risk of second tumors, it is used in many programs of unrelated donor transplants, especially at low doses (200 rads or 2 cGy). In the Japanese program using a de-escalating dose of TBI, best results are seen when using TBI 2 cGy.
A radiation-free regimen has been proposed by the European Group for Blood and Marrow Transplantation (EBMT) SAA working party: this includes fludarabine (120 mg/m 2 ), CY (1200 mg/m 2 ) and antithymocyte globulin (15 mg/kg). 17 In young patients under the age of 15 years, the outcome is excellent with 84% 2-year survival and 5% rejection. In older patients the results are less favourable with 61% survival and 32% rejection. Therefore, it may be that young children, with a short-interval diagnosis transplant may be successfully allografted with a radiation-free regimen. This may not be the case for adults.
Currently, it would seem advisable to start the search for an unrelated donor in all patients with severe and very SAA, especially if they have failed one course of IST.
IST
An ALG remains the drug of first choice for the treatment of SAA: 1, 6, 18 combined therapy of ALF with CsA produces survival between 60 and 90%. 8, 19 Response to ALG þ CsA is usually slow, with median time to response of over 100 days, and 20-40% fail to respond to a first course of IST requiring a second course of ALG. This can rescue a significant proportion of nonresponders. 20 Relapse of cytopenia is an additional problem, 21 and requires very slow tapering of CsA: some patients, however, become CsA dependent.
Currently, IST is first-line treatment for all patients above the age of 50 years, for patients who lack an HLAidentical donor, and for patients with non-severe aplastic anemia. Horse 
Growth factors
The use of several growth factors has been explored, and includes GM-CSF, IL3, granulocyte CSF (G-CSF), and stem cell factor (SCF) growth factors, especially G-CSF, have been used, in conjunction with ALG þ CsA 22 and some studies have seen a relatively high risk of clonal disorders in children given G-CSF long term. 23 A prospective randomized study has failed to show an advantage or a disadvantage for patients receiving G-CSF. 24 Conclusions AA is a rare disorder and should be treated in experienced centers. Significant improvement has been achieved in the setting of BMT, and for IST in young children with severe disease. International cooperation is also considered important to address the many questions that still need to be answered.
